R&D

Five things for pharma marketers to know: Monday, November 27, 2017

Five things for pharma marketers to know: Monday, November 27, 2017

By

Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up

Five things for pharma marketers to know: Friday, November 3, 2017

Five things for pharma marketers to know: Friday, November 3, 2017

By

Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval

Five things for pharma marketers to know: Wednesday, June 14, 2017

Five things for pharma marketers to know: Wednesday, June 14, 2017

By

Sanofi to boost investment in biologics R&D; Sage's awareness campaign criticized; PatientsLikeMe poll finds 95% of patients want some costs of drugs covered

Five things for pharma marketers to know: Thursday, June 8, 2017

Five things for pharma marketers to know: Thursday, June 8, 2017

By

Novartis CAR-T drug boasts competitive response rates; WPP reports slowing sales for healthcare business; AZ sells migraine drug

Five things for pharma marketers to know: Friday, May 19, 2017

Five things for pharma marketers to know: Friday, May 19, 2017

By

Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness

MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

By

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.